AAP Compound Metabolism: Cytochrome P450 Degradation and Metabolite Identification

A study by Johannes Doering investigates the metabolic degradation of antimycobacterial Nα-Aroyl-N-aryl-phenylalanine amides (AAPs). The dataset, last updated in June 2026, likely contains results from LC-MS/MS analysis identifying metabolites formed via cytochrome P450 enzymes. The research demonstrates that enzyme inhibitors slow AAP degradation in vitro and in vivo.

Use Cases

• Identify metabolic pathways for AAP compounds based on LC-MS/MS metabolite data.
• Screen for cytochrome P450 enzyme inhibitors that improve compound stability based on in vitro and in vivo results.
• Guide chemical modification of AAPs to achieve metabolic stability based on identified metabolite structures.
• Model structure-activity relationships for antimycobacterial agents based on the ortho-phenylenediamine oxidation mechanism.

Strengths

• Includes data from both in vitro and in vivo experiments demonstrating the effect of cytochrome P450 inhibitors.
• Metabolite identification is performed using LC-MS/MS, a standard analytical technique.
• Dataset is focused on a specific class of antimycobacterial compounds (AAPs) with a described mechanism of action.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect experimental bias inherent to the specific study methodology.

Provenance

Source

figshare, author Johannes Doering.

Collection Method

Experimental study using LC-MS/MS analysis and in vitro/in vivo assays.

Freshness

Last updated 2026-06-02 12:06:55; freshness should be verified.